Schedule III [21 CFR 1308.13]
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Source: DEA Office of Diversion Control: Section 1308: Schedules of Controlled Substances
(f)
Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation:
Readers wanting to explore the intricacies of steroid nomenclature may find this steroid crib sheet useful.
(1)
4000
Anabolic steroids (see §1300.01 of this chapter)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Anabolic Steroids
From 21 CFR 1300.01 Definitions relating to controlled substances
Anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Effective 27 Jan 2012, 77 FR 4228 replacement for:
[From 21 CFR 1300.01 Definitions relating to controlled substances]
…(4) The term anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
[From 21 CFR 1308.02 Definitions]
…(b) The term anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins and corticosteroids) that promotes muscle growth, and includes:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(1)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(2)
3α,17β-Dihydroxy-5α-androstane
UK: MDA Part III Class C Section 1(b) 5α-Androstane-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(3)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(4)
1-Androstenediol (3β,17β-Dihydroxy-5α-androst-1-ene)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(5)
1-Androstenediol (3α,17β-Dihydroxy-5α-androst-1-ene)
UK: MDA Part III Class C Section 1(b) 1-Androstenediol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(6)
4-Androstenediol (3β,17β-Dihydroxyandrost-4-ene)
UK: MDA Part III Class C Section 1(b) Androst-4-ene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(7)
5-Androstenediol (3β,17β-Dihydroxyandrost-5-ene)
CA: CDSA Schedule IV Section 23 Subsection 3 Androstenediol
UK: MDA Part III Class C Section 1(b) 5-Androstene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(8)
1-Androstenedione ([5α]-Androst-1-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 1-Androstenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(9)
4-Androstenedione (Androst-4-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 4-Androstene-3,17-dione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(10)
5-Androstenedione (Androst-5-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 5-Androstenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(11)
Bolasterone (7α,17α-Dimethyl-17β-hydroxyandrost-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 5 Bolasterone
UK: MDA Part III Class C Section 1(b) Bolasterone
(12)
Boldenone (17β-Hydroxyandrost-1,4-diene-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Boldenone (17β-Hydroxyandrost-1,4,-diene-3-one)
Effective 27 Feb 1991, 56 FR 5753 added:
Boldenone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(13)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(14)
Calusterone (7β,17α-Dimethyl-17β-hydroxyandrost-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 9 Calusterone
UK: MDA Part III Class C Section 1(b) Calusterone
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Chlorotestosterone (4-Chlortestosterone)
Chlorotestosterone is a synonym for Clostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(15)
Clostebol (4-Chloro-17β-hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Clostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(16)
Dehydrochloromethyltestosterone (4-Chloro-17β-hydroxy-17α-methylandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Dehydrochlormethyltestosterone
UK: MDA Part III Class C Section 1(b) 4-Chloromethandienone
⇒
PubChem: 16395944; ChemSpider: 88972; Erowid: Steroids; Wikipedia: 4-Chlorodehydromethyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(17)
Desoxymethyltestosterone (17α-Methyl-5α-androst-2-en-17β-ol; Madol)
UK: MDA Part III Class C Section 1(b) Desoxymethyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(18)
Δ1-Dihydrotestosterone (1-Testosterone; 17β-Hydroxy-5α-androst-1-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(19)
4-Dihydrotestosterone (17β-Hydroxyandrostan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Dihydrotestosterone (4-Dihydrotestosterone)
CA: CDSA Schedule IV Section 23 Subsection 2 Androstanolone
UK: MDA Part III Class C Section 1(b) Stanolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(20)
Drostanolone (17β-Hydroxy-2α-methyl-5α-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Drostanolone
CA: CDSA Schedule IV Section 23 Subsection 11 Drostanolone
UK: MDA Part III Class C Section 1(b) Drostanolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(21)
Ethylestrenol (17α-Ethyl-17β-hydroxyestr-4-ene)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Ethylestrenol
CA: CDSA Schedule IV Section 23 Subsection 14 Ethylestrenol
UK: MDA Part III Class C Section 1(b) Ethyloestrenol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(22)
Fluoxymesterone (9-Fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Fluoxymesterone
CA: CDSA Schedule IV Section 23 Subsection 16 Fluoxymesterone
UK: MDA Part III Class C Section 1(b) Fluoxymesterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(23)
Formebolone (2-Formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Formebulone (Formebolone)
CA: CDSA Schedule IV Section 23 Subsection 17 Formebolone
UK: MDA Part III Class C Section 1(b) Formebolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(24)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(25)
13β-Ethyl-17β-hydroxygon-4-en-3-one
Effective 13 Oct 2006, 71 FR 60426 replacement for:
13β-Ethyl-17α-hydroxygon-4-en-3-one
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(26)
4-Hydroxytestosterone (4,17β-Dihydroxyandrost-4-en-3-one)
[With thanks to Jan of Palo Alto for reporting an error in the structural diagram shown previously for this substance.]
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(27)
4-Hydroxy-19-nortestosterone (4,17β-Dihydroxy-estr-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 15 4-Hydroxy-19-nortestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(28)
Mestanolone (17α-Methyl-17β-hydroxy-5α-androstan-3-one)
UK: MDA Part III Class C Section 1(b) Mestanolone
(29)
Mesterolone (1α-Methyl-17β-hydroxy-[5α]-androstan-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Mesterolone (1αMethyl-17β-hydroxy-[5α]-androstan-3-one)
Effective 27 Feb 1991, 56 FR 5753 added:
Mesterolone
CA: CDSA Schedule IV Section 23 Subsection 21 Mesterolone
UK: MDA Part III Class C Section 1(b) Mesterolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(30)
Methandienone (17α-Methyl-17β-hydroxyandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandienone
CA: CDSA Schedule IV Section 23 Subsection 22 Metandienone
UK: MDA Part III Class C Section 1(b) Methandienone
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandranone
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(31)
Methandriol (17α-Methyl-3β,17β-dihydroxyandrost-5-ene)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandriol
CA: CDSA Schedule IV Section 23 Subsection 24 Methandriol
UK: MDA Part III Class C Section 1(b) Methandriol
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandrostenolone
Methandrostenolone is a synonym for Methandienone
Effective 29 Aug 2012, 77 FR 44456 added (and renumbered subsequent entries):
On 23 Nov 2011, 76 FR 72355 proposed to add (and to renumber subsequent entries):
(32)
Methasterone (2α,17α-Dimethyl-5α-androstan-17β-ol-3-one)
See also CSA Schedule III Section f Subsection 1 Item 73 2α,17α-Dimethyl-17β-hydroxy-5α-androstan-3-one
⇒
PubChem: 237186; ChemSpider: 207079; Bluelight: Superdrol; Erowid: Steroids; Wikipedia: Methasterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(33)
Methenolone (1-Methyl-17β-hydroxy-5α-androst-1-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methenolone
CA: CDSA Schedule IV Section 23 Subsection 23 Metenolone
UK: MDA Part III Class C Section 1(b) Methenolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(34)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(35)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(36)
17α-Methyl-3β,17β-dihydroxyandrost-4-ene
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(37)
17α-Methyl-4-hydroxynandrolone (17α-Methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(38)
Methyldienolone (17α-Methyl-17β-hydroxyestra-4,9(10)-dien-3-one)
(39)
Methyltrienolone (17α-Methyl-17β-hydroxyestra-4,9,11-trien-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
Methyltrienolone (17α-Methyl-17β-hydroxyestra-4,9-11-trien-3-one)
CA: CDSA Schedule IV Section 23 Subsection 26 Metribolone
UK: MDA Part III Class C Section 1(b) Metribolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(40)
Methyltestosterone (17α-Methyl-17β-hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methyltestosterone
CA: CDSA Schedule IV Section 23 Subsection 25 Methyltestosterone
UK: MDA Part III Class C Section 1(b) Methyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(41)
Mibolerone (7α,17α-Dimethyl-17β-hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Mibolerone
CA: CDSA Schedule IV Section 23 Subsection 27 Mibolerone
UK: MDA Part III Class C Section 1(b) Mibolerone
(42)
17α-Methyl-Δ1-dihydrotestosterone (17β-Hydroxy-17α-methyl-5α-androst-1-en-3-one; 17α-Methyl-1-testosterone)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
17α-Methyl-Δ1-dihydrotestosterone (17bβ-Hydroxy-17α-methyl-5α-androst-1-en-3-one; 17α-Methyl-1-testosterone)
⇒
PubChem: 7092657; ChemSpider: 5442174; Bluelight: Methyl-1-Testosterone; Drugs Forum: M-1-T; Erowid: Steroids; Wikipedia: Methyl-1-testosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(43)
Nandrolone (17β-Hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Nandrolone
CA: CDSA Schedule IV Section 23 Subsection 28 Nandrolone
UK: MDA Part III Class C Section 1(b) Nandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(44)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(45)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(46)
19-Nor-5-androstenediol (3β,17β-Dihydroxyestr-5-ene)
UK: MDA Part III Class C Section 1(b) 19-Nor-5-androstene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(47)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(48)
19-Nor-4,9(10)-androstadienedione (Estra-4,9(10)-diene-3,17-dione)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(49)
19-Nor-4-androstenedione (Estr-4-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 19-Nor-4-androstene-3,17-dione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(50)
19-Nor-5-androstenedione (Estr-5-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 19-Norandrostenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(51)
Norbolethone (13β,17α-Diethyl-17β-hydroxygon-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 29 Norboletone
UK: MDA Part III Class C Section 1(b) Norboletone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(52)
Norclostebol (4-Chloro-17β-hydroxyestr-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 30 Norclostebol
UK: MDA Part III Class C Section 1(b) Norclostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(53)
Norethandrolone (17α-Ethyl-17β-hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Norethandrolone
CA: CDSA Schedule IV Section 23 Subsection 31 Norethandrolone
UK: MDA Part III Class C Section 1(b) Norethandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(54)
Normethandrolone (17α-Methyl-17β-hydroxyestr-4-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(55)
Oxandrolone (17α-Methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxandrolone
CA: CDSA Schedule IV Section 23 Subsection 33 Oxandrolone
UK: MDA Part III Class C Section 1(b) Oxandrolone
⇒
PubChem: 5878; ChemSpider: 5667; Bluelight: Oxandrolone; Drugs Forum: Oxandrolone; Erowid: Steroids; Wikipedia: Oxandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(56)
Oxymesterone (17α-Methyl-4,17β-dihydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxymesterone
CA: CDSA Schedule IV Section 23 Subsection 34 Oxymesterone
UK: MDA Part III Class C Section 1(b) Oxymesterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(57)
Oxymetholone (17α-Methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxymetholone
CA: CDSA Schedule IV Section 23 Subsection 35 Oxymetholone
UK: MDA Part III Class C Section 1(b) Oxymetholone
⇒
PubChem: 3032303; ChemSpider: 4444502; Bluelight: Oxymetholone; Erowid: Steroids; Wikipedia: Oxymetholone
Prostanozol
Prostanozol, O-tetrahydropyran-2-yl
Effective 29 Aug 2012, 77 FR 44456 added (and renumbered subsequent entries):
On 23 Nov 2011, 76 FR 72355 proposed to add (and to renumber subsequent entries):
(58)
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole)
[There is much confusion surrounding the name Prostanozol. The culprit seems to be the World Anti-Doping Agency (WADA), which every year updates their list of Prohibited Substances.
For 2009 (and later) it reads:
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole), depicted at left, above.
For 2008 (and earlier) it reads:
Prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol), depicted at left, below.
Given these names describe distinctly different substances WADA’s explanation—“The nomenclature of Prostanozol has been changed to better follow the International Union of Pure and Applied Chemistry (IUPAC) rules”—has a certain… CYA quality. Not very helpful WADA. Definitely not very sporting.]
For 2009 (and later) it reads:
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole), depicted at left, above.
For 2008 (and earlier) it reads:
Prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol), depicted at left, below.
Given these names describe distinctly different substances WADA’s explanation—“The nomenclature of Prostanozol has been changed to better follow the International Union of Pure and Applied Chemistry (IUPAC) rules”—has a certain… CYA quality. Not very helpful WADA. Definitely not very sporting.]
UK: MDA Part III Class C Section 1(b) Prostanozol
See also CSA Schedule III Section f Subsection 1 Item 89 [3,2-c]Pyrazole-5α-androstan-17β-ol
UK: MDA Part III Class C Section 1(b) Prostanozol, O-tetrahydropyran-2-yl
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Stanolone
Stanolone is a synonym for 4-Dihydrotestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(59)
Stanozolol (17α-Methyl-17β-hydroxy-[5α]-androst-2-eno[3,2-c]pyrazole)
Effective 13 Oct 2006, 71 FR 60426 replacement for:
Stanozolol (17α-Methyl-17α-hydroxy-[5α]-androst-2-eno[3,2-c]pyrazole)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Stanozolol
CA: CDSA Schedule IV Section 23 Subsection 38 Stanozolol
UK: MDA Part III Class C Section 1(b) Stanozolol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(60)
Stenbolone (17β-Hydroxy-2-methyl-[5α]-androst-1-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 39 Stenbolone
UK: MDA Part III Class C Section 1(b) Stenbolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(61)
Testolactone (13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Testolactone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(62)
Testosterone (17β-Hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Testosterone
CA: CDSA Schedule IV Section 23 Subsection 40 Testosterone
UK: MDA Part III Class C Section 1(b) Testosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(63)
Tetrahydrogestrinone (13β,17α-Diethyl-17β-hydroxygon-4,9,11-trien-3-one)
UK: MDA Part III Class C Section 1(b) Tetrahydrogestrinone
⇒
PubChem: 25320811 6857686; ChemSpider: 5257020; Bluelight: Tetrahydrogestrinone; Erowid: Steroids; Wikipedia: Tetrahydrogestrinone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(64)
Trenbolone (17β-Hydroxyestr-4,9,11-trien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Trenbolone and
[With thanks to Jan of Palo Alto for reporting an error in the structural diagram shown previously for this substance.]
CA: CDSA Schedule IV Section 23 Subsection 43 Trenbolone
UK: MDA Part III Class C Section 1(b) Trenbolone
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(65)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(67)
6-Bromo-androsta-1,4-diene-3,17-dione
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(68)
4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
See also CSA Schedule III Section f Subsection 1 Item 72 4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(69)
4-Chloro-17α-methyl-androst-4-ene-3β,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(70)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(71)
4-Chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(72)
4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
See also CSA Schedule III Section f Subsection 1 Item 68 4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(73)
2α,17α-Dimethyl-17β-hydroxy-5α-androstan-3-one
See also CSA Schedule III Section f Subsection 1 Item 32 Methasterone
⇒
PubChem: 237186; ChemSpider: 207079; Bluelight: Superdrol; Erowid: Steroids; Wikipedia: Methasterone
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(74)
2α,17α-Dimethyl-17β-hydroxy-5β-androstan-3-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(75)
![3D rendering of [3,2-c]-Furazan-5α-androstan-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of [3,2-c]-Furazan-5α-androstan-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(76)
[3,2-c]-Furazan-5α-androstan-17β-ol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(77)
3β-Hydroxy-estra-4,9,11-trien-17-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(78)
17α-Methyl-androst-2-ene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(79)
17α-Methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(80)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(81)
18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(82)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(83)
17α-Methyl-androstan-3-hydroxyimine-17β-ol
![3D rendering of 17β-Hydroxy-androstano[2,3-d]isoxazole](data:image/png;base64,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 "Click for a 3D rendering of 17β-Hydroxy-androstano[2,3-d]isoxazole")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(85)
17β-Hydroxy-androstano[2,3-d]isoxazole
![3D rendering of 17β-Hydroxy-androstano[3,2-c]isoxazole](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAOAAAACdCAIAAAAi8+OpAAAACXBIWXMAAC4jAAAuIwF4pT92AAAAHXRFWHRTb2Z0d2FyZQBHUEwgR2hvc3RzY3JpcHQgOC43MQM/aDQAAAzCSURBVHic7Z2xj5zGF8ff/mS7SzHbp5lVUkdmu0jRFVwZKQ2rVCnB/wE0bqIUbOUa2nRscbJkKQVbpEnHpXAVRYIyRQqQLEuJ3PArXjzmYI8bYBhmb99HlnXLsTxu73vz3gwz31nVdQ0EYSr/W/oGCKIPEihhNCRQwmhIoITRkEAJoyGBEkZDAiWMhgRKGA0JlDAaEihhNCRQwmhIoITRkEAJoyGBEkZDAiWMhgRKGA0JlJCjqsDzYL2G1QrWa/A8qKpP312t2ud3j4yCBEpIUFWw2QBjkGVQ15BlwBhsNnc0Og8rWvJBPIznAWMQhncOBgFUFUQRAMBqBS0hdY+MggRKSLBeQ5YB53cOFgVst1CWACRQYlnuU5s4frLiVCEtqkEJCRiDomgfLApg7NPLur7zTxEkUEICx4E4bh+MY3CcuSM/mTsA8RgIQ9hsAABcFziHooA4hjiGPJ87MrWghASMQZ5DVcF2C6sVbLdQVZDnd1L8PFAniTAaSvHEAI7Ho/jatm0NEakFvQiqqrq9vW0esSyLDU/Qq8Zwkh7lUAt6KVxfXzdfpmk6ogm0bRsbUT3NJ1An6UIY0VgaAgn0UuB3H1SOawIty2p9MTck0EuhJdBzgQR6KTSz/Oj2T1xEm9xJoJdCU1KjS1KhbBIoMSPT5aWt10UCvRSavaLpLSh1kogZGS1Q/cNVNFB/KTTbvCntH2NMW/MJ1IJeDqoaP53qBBLoeXE8Hq+vr9fr9X6/H/F20Tea+KCSWlCiTVEUnufh83TXdYMg2Gw2zblFMigZG6IWlLhDVVVBEGy32+PxGEVRmqZhGOZ5zjm/vr7e7XZFd7XQPWCWn64wakGJ/4jjeLvdxnHsum6e567r4nHOeZqmaZre3t5uNpsgCCoJDwVsQScWo5xznX15EqihYLnpeZ5t23mehy3TBAAAEN+K43iz2cTddW2nmJLoq6r6448/nj59OvoKg6kJwxAtpW3bWZbJvKUsS9/3AcCyrDRN7zstTVMA8H1/xC2FYSi6VoyxsiyHXmQcJFCDQJ0xxjjnSZIMfXue56ghrAe6J6BAwzCUv2AYhlhxMsZc102SpCxLzrlt20NvbxwkUFOIogjLuxEtXJMkScR1uu0cAPQ0sUiWZV1dtk4YJPQpkECXR6y+cF1XVeoULXEURc3jPQLNssz3faxQOee+7/cUGFhRSFYgUyCBLsmIclOesizFxYUoLctqnTZIl01s2+acz12MkkCXYWK5KU+WZc3mWdSOSZK4rou6tCxLXpeCPM+xAJjhrj9BAl2AZpmoJ6IocK+urlzXFSP2OOY/+rJJkgDArH9gJNAFAADHcbSN1CDNoaiJumyCeUDV1bqQccMCrFarccvSDQxdVRXOEMCuvXLoSRIxCcZYFEVFUQRBMMf1SaDEVLCPtd/vh86ukoEESijA933HcXa7ncyclUGQQAk1RFHEGPM8T+1lSaCEGrAYPRwO42b73wcJlFCGbdu+7wdB0LJ6nAIJ9GxYdbZ66R5ZHJxl4nmeqmKUBEooJkmSoihUJXoSKKEYnEK13+8Ph8P0q5FACfU4juO6rud58gv67oOcRYYRx3GrYcBp6nowsOi8D9d14zguimLiWmcS6DCKotC/04WgNXHCZL16nmdZ1vTPhwQ6jDP1KdZMEARFUSjJLSTQYbQEqtlm4yzAsfooipR8ONRJGsb5bpehB7TocV1XeExMhAQ6jFaroDPjd2fuGjiX1/M8xthJm4lxkEAnobkk3W63q4/ojCtJEATH4zFJEoV5hgQ6mGbPVLNATS4wjsfjfr8XC+pVQQKdhGaBinCmDSZUVbXb7RzHwWVPCiGBDka0EPrbM/3bFEmCpWcURcqvTMNM49E/xmRmisfH7mmaznF7F9qCVlU1eg3NxNYL56GNm402cRcYDKpwsiZeLQgC3/fneqg203Jmk0EXA/zx7zOC60E8IBlhu4CryMXbhy6NnxI6DEMR+qQl2Ag0ON1dlkBbPjD9RnA9FxmhklYslAvWbYN+BAw96F1pmuIfJIZumn0yxhzHiaJonIsEmpTM6kBxKQI96aSF3GcE1wOqRLIFatl2imbs5uZGxnX2ZGjJ80Vox3HE10JSZVlGUeQ4Dl5zqFKxSzSr7029oEDLstTm/fKgBJvylfHQklTJSePjLMvQXh5ftjT0YGisPseFzvM8TdPuD3hSqf03k2WZHm+pZQSa5/mzZ89G/NUOZVASl/fpxNP6f4WDkngrCz8Yuv9quAIYHzk+GLoFut496C5mWVbXyXEOlhGoZVlfffXVq1evRueXB2mWm4O6QTJOx/0q6Vdb+pHut4Sme4SFn1hPaGxi+0Pf9/YmPUqd2zCsyQICxR9PJJqJlVAXyR0FHrxCj3knfrd7/MF83XTYOqlCcfO40czJ0Jzzk6HxM8StP7onNGdnDvpYkiQRDreWZWEtNLRvNxrdAu3x8Vei1NG94y49v3Ic9mvdfL+wziV0D8KLWZutaa1ZoGVZ4rgGfn0yzeG3mvlFUqnyZdwgTibNJEmaKplS8w0NjYXy3KHNQatAHccRruZ5nsu0lF2ldvPX0I7wCFo6SNMUW5H+mq8L/lkikrfaE3rQ1gsjQpuAPoHiJNZmDhrUUp6s2bVlt/puJv35559fvHjRX/OdpDnZBzPJ0NA3NzcvXrwYsfVCM7S2XY6mo0mg2DnoqV1aSu3xqG6e+ezZM83ZTVSHKJe5h6kNCb0gOgRalqX8sJnkOFxd1y9fvgQAzU7viO/7ekYBjQq9CDqm2+33+6IoJD3MHcfBXH84HHCSdhAElmXh8eZMom+++QaWm4E2Lm5RFE2zjXEzgMaFvr29FVOoGGNnsx517r+A6TuV3Nem4oiVujsdQHesR5KWIkds3jUuNI6fiLg6d4OdyLy/YLV7PQmlYvfiHAV61qEXYd4U73ke51zVIlSR/ZVcjTgLZhTor7/+atv2999/b+ZChUX4888/379/L15+8cUXn332mZ7Qv//+e/OlztBTmFGgV1dXV1dX813/HPnyyy+XCv38+fOlQk9B0ZqkqgLPg/UaVitYr8HzQPV2JMRlokKgVQWbDTAGWQZ1DVkGjMFmQxptsaDJ/Fn4259ERYoPAnBdED0hzv/7OgiAOjTENFS0oIcDdK3MXBdUWJQTF46iFN9dKs45pXhiOioEyhh0vfKLAmh0qcPqLhcSegoqBOo4EMftg3EMH6feEILWY5ILCT0FFZ2kMITNBgDAdYFzKAqIY4hj+DglmSBGoyjF5zlUFWy3sFrBdgtVBXlOKZ6YjqInSYxBFNGgEqGcGd3t3r59+9tvv/3777/zhTgvupWftlpwwdATmVGgn3/++bfffvvDDz/MF4J49MwoUMZYkiRqd7g/HA6e5wVBoOqChOHMa2CLO9zv9/sppqlVVaEu1+v1brerqupslisQk5ndYTkMQ875iB3uq6qK43i32wldhmGIK5UdGmG9GHRYgA/a4b6pS8/zAAAXyzdXJiHNmb/Eo0XHuhKJpXPyxkytMwf5JihBeGlLWnooBF1G5B0fHgH6Fp399NNP33333V9//dU8+O7duzdv3vz444+2bXPO5XWJZ97c3AxynplI0+hGxqVxptDnsiBTCfoE+uHDh/4T/vnnn+5BmZZVg4FW027u9evXtm3btv3q1SsNxjsP+io+bgz1qB9qxTjdE/TBKwsV4hHf93FV+3wC0uk8ZSy6BQpQt1JiswyeaBGq3OZOvm1WnoJl3JYvgQUEynndbA6EQG9ubqCxhc/oX7MSo9BxglNSbMxkdHqmLCDQNK05r8UnLwT6yy+/KHRsG221nOd5v7lhFEVYgzqO0xXQlGJDg9Hp2bGAQOu6dpxPiX6+ka6evZHuO7/fmh5BJ2zf93uayaFSm6+GPneWEWie14zV2DzNPRQrud3HHMNGkslaoa/+42MZgdZ1HYY12lzqeVbQs2FSa39E5aF79Efl5oMsJtC6ri2r9n1NAkVaGXxoDVB3fAzl39UKROWmJEsKNE1rAK0CrRtasSxr6BadiNjLcGixKJpq/J/KTRmWFGhd166rW6BImqaO4yySWHELGyo3JVnVZzL1n7hMdHjUPyZub2+b8/nRknzB+3n0kECHwTlvzuenuf1zQymeMBodM+oJYjSU4ofx9u3bv//+W7x88uTJ119//fTp0wVv6XFDKZ4wGkrxwzhfL+0zhQRKGA0JlDAaEihhNNSLHwwVnTohgQ6mNe5Bep0VSvGE0ZBACaMhgRJGQ0+SCKOhFpQwGhIoYTQkUMJoSKCE0ZBACaMhgRJGQwIljIYEShgNCZQwGhIoYTQkUMJoSKCE0ZBACaMhgRJGQwIljIYEShjN/wHGOEsa006NBgAAAABJRU5ErkJggg== "Click for a 3D rendering of 17β-Hydroxy-androstano[3,2-c]isoxazole")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(86)
17β-Hydroxy-androstano[3,2-c]isoxazole
![3D rendering of 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(87)
4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol [sic]
![3D rendering of [3,2-c]Pyrazole-androst-4-en-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of [3,2-c]Pyrazole-androst-4-en-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(88)
[3,2-c]Pyrazole-androst-4-en-17β-ol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(89)
[3,2-c]Pyrazole-5α-androstan-17β-ol
UK: MDA Part III Class C Section 1(b) Prostanozol
See also CSA Schedule III Section f Subsection 1 Item 58 Prostanozol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. renumbered:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(90)
Any salt, ester, or ether of a drug or substance described in this paragraph. Except such term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.
11 March 2016 · 
· Isomer Design
· Isomer Design